SCHEMBL6495379

SCHEMBL6495379

CC(=O)Oc1ccc(CN(C(C)=O)c2nc(Br)ccc2[N+](=O)[O-])c(Cl)c1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DCTPP1 Q9H773 1/20 0.36
MAPT P10636 5/20 0.34
ALDH1A1 P00352 1/20 0.34
LMNA P02545 1/20 0.34
RAF1 P04049 1/20 0.34
HPGD P15428 1/20 0.34
MAPK1 P28482 1/20 0.34
GFER P55789 1/20 0.34
PAX8 Q06710 1/20 0.34
KMT2A Q03164 4/20 0.33
MEN1 O00255 3/20 0.33
NPC1 O15118 2/20 0.33
TLR9 Q9NR96 2/20 0.33
KDM4E B2RXH2 1/20 0.32
HTT P42858 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
POLB P06746 2/20 0.32
PLA2G1B P04054 1/20 0.32
ATG4B Q9Y4P1 1/20 0.32
MMP14 P50281 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6503124 0.92 DCTPP1 (0.35) DCTPP1MAPTALDH1A1LMNARAF1
SCHEMBL6300189 0.88 TSHR (0.41) MAPTALDH1A1LMNAHPGDMAPK1
SCHEMBL6298753 0.83 MEN1 (0.41) MAPTALDH1A1MAPK1KMT2AMEN1
SCHEMBL6301015 0.83 EIF4E (0.35) ALDH1A1SMN1; SMN2EIF4E
SCHEMBL6299835 0.83 VCAM1 (0.41) DCTPP1MAPTALDH1A1LMNAKMT2A
SCHEMBL6299192 0.83 KMT2A (0.45) MAPTALDH1A1LMNAHPGDMAPK1
SCHEMBL6493386 0.81 TXNRD1 (0.31) MAPTLMNAHTTNPSR1TXNRD1
SCHEMBL6492327 0.81 KMT2A (0.34) MAPTALDH1A1LMNAHPGDMAPK1
SCHEMBL6299180 0.80 PTGES (0.37) MAPTALDH1A1KMT2AMEN1NPC1
SCHEMBL27556260 0.78 THRB (0.39) MAPTALDH1A1LMNAMAPK1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6890934-B2 Sulfonamide compounds and uses thereof as medicines FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2005-05-10 US disclosed
US-20030171396-A1 Sulfonamide compounds and uses thereof as medicines FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2003-09-11 US disclosed
US-6573274-B1 Treatment of the diseases curable based on a hypoglycemic action, and the diseases curable based on a cGMP-PDE inhibitory action, a smooth muscle relaxing action, a bronchodilating action, a vasodilating action, a smooth muscle FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2003-06-03 US disclosed
EP-1136492-A1 SULFONAMIDE COMPOUNDS AND USES THEREOF AS MEDICINES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-09-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030171396-A1 Sulfonamide compounds and uses thereof as medicines PDE2A, PDE3A, PDE5A DCTPP1 2259/4885MAPT 4144/4885ALDH1A1 476/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.